Terlipressin acetate is a Vasotocin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective Vasotocin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research In Vitro Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells. Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Concentration: 25 nM Incubation Time: 24 hours, 48 hours, 72 hours Result: Significantly increased the proliferation of IEC-6 cells. In Vivo Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Vasotocin V1 receptor